HIV prevention shot achieved a 96% success rate in clinical trials, but accessibility and regulatory hurdles remain a ...

HIV research programs have been halted, and many treatment clinics are still closed, despite a waiver for “life-saving” ...

USAID offers (or offered) training on preventing mass atrocities, recognizing that infringement on religious freedom is a key ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

In this month’s issue, the Sexpert advises readers on how to navigate discussions of PrEP and sexual health while in the ...

Cabotegravir – given the trade name Apretude – can be dosed just six times a year and showed superior results to daily, oral therapy with Gilead's widely used Truvada (emtricitabine and ...

Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

This story was originally published by Healthbeat. Sign up for their public health newsletters at healthbeat.org/newsletters.

Data from both studies showcased the superiority of twice-yearly injectable, lenacapavir, compared to once-daily oral Truvada and background HIV incidence rates, prompting Gilead to unblind the ...

Please be advised that today's conference is being recorded. I would now like to hand the conference over to Sally Schwartz, Vice President of Investor Relations. Hello everyone and welcome to our ...

Blake Brittain reports on intellectual property law, including patents, trademarks, copyrights and trade secrets, for Reuters Legal. He has previously written for Bloomberg Law and Thomson Reuters ...